MET and neoplasm: Concordant MET RNA‐ISH and c‐MET IHC protein expression was present in 173 (72.08%) patients while nonconcordance was observed in 32 (13.33%) and 35 (14.58%) of the study cohort in patients with low MET RNA‐ISH, high c‐MET IHC protein expressing tumours and in high MET RNA‐ISH and low c‐MET IHC protein expressing tumour, respectively (Fig. 2H).